Opicinumab - Biogen

Drug Profile

Opicinumab - Biogen

Alternative Names: Anti-LINGO 1; Anti-LINGO-1 antibody; BIIB-033

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Dyax
  • Developer Biogen
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Neuropsychotherapeutics
  • Mechanism of Action Cell differentiation stimulants; LINGO-1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Optic neuritis

Most Recent Events

  • 25 Oct 2017 Pharmacodynamics data from a preclinical trial in Optic neuritis presented at the 7th Joint ECTRIMS – ACTRIMS meeting (ECTRIMS – ACTRIMS - 2017)
  • 26 Sep 2017 Phase-II clinical trials in Multiple sclerosis (Adjunctive treatment) in USA (IV) (NCT03222973)
  • 24 Aug 2017 Phase-II development for Multiple sclerosis is ongoing in Canada, Czech Republic, France, Hungary, Italy, Netherlands, Poland, Russia, Serbia, Spain, USA, United Kingdom (IV,infusion) (Biogen pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top